Antigenic Cancer Cells Grow Progressively in Immune Hosts without Evidence for T Cell Exhaustion or Systemic Anergy by Wick, Maresa et al.
 
229
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/97/07/229/10 $2.00
Volume 186, Number 2, July 21, 1997 229–238
 
Antigenic Cancer Cells Grow Progressively in Immune Hosts
without Evidence for T Cell Exhaustion or Systemic Anergy
 
By Maresa Wick,
 
*
 
 Purnima Dubey,
 
*
 
 Hartmut Koeppen,
 
*
 
Christopher T. Siegel,
 
‡
 
 Patrick E. Fields,
 
§
 
 Lieping Chen,
 
i
 
 
Jeffrey A. Bluestone,
 
§
 
 and Hans Schreiber
 
*
 
From the 
 
*
 
Department of Pathology, 
 
‡
 
Department of Surgery, and 
 
§
 
Ben May Institute for Cancer 
Research, The University of Chicago, Chicago, Illinois 60637; and the 
 
i
 
Bristol-Myers Squibb 
Pharmaceutical Research Institute, Seattle, Washington 98121
 
Summary
 
One enigma in tumor immunology is why animals bearing malignant grafts can reject normal
grafts that express the same nonself-antigen. An explanation for this phenomenon could be that
different T cell clones react to the normal graft and the malignant cells, respectively, and only
the tumor-reactive clonotypes may be affected by the growing tumor. To test this hypothesis,
we used a T cell receptor transgenic mouse in which essentially all CD8
 
1
 
 T cells are specific for
a closely related set of self-peptides presented on the MHC class I molecule L
 
d
 
. We find that
the tumor expressed L
 
d
 
 in the T cell receptor transgenic mice but grew, while the L
 
d
 
-positive
skin was rejected. Thus, despite an abundance of antigen-specific T cells, the malignant tissue
grew while normal tissue expressing the same epitopes was rejected. Therefore, systemic T cell
exhaustion or anergy was not responsible for the growth of the antigenic cancer cells. Expres-
sion of costimulatory molecules on the tumor cells after transfection and preimmunization by
full-thickness skin grafts was required for rejection of a subsequent tumor challenge, but there
was no detectable effect of active immunization once the tumor was established. Thus, the fail-
ure of established tumors to attract and activate tumor-specific T cells at the tumor site may be
a major obstacle for preventive or therapeutic vaccination against antigenic cancer.
 
O
 
ne of the most important questions in tumor immu-
nology is why the immune system often fails to elim-
inate antigenic cancers. A variety of reasons could account
for the lack of efficient immune responses to antigenic tu-
mor cells. For example, deficiencies in quantity, processing,
presentation, or affinity may reduce the antigenicity of cer-
tain tumor antigens. Lack of expression of costimulatory
molecules on the tumor cells can lead to anergy of tumor-
reactive T cells (for review see reference 1). Expression of
Fas ligand on tumor cells can induce apoptosis of T cells
entering the site of tumor growth (2–4). In addition, tu-
mors and/or their surrounding stroma may produce immu-
nosuppressive factors such as TGF-
 
b
 
 that oppose effective
stimulation, particularly of naive T cells (5–7). Another
critical factor may be that cancer cells, like infectious
agents, are proliferating antigens, and the precursor fre-
quency of specifically reactive T cells may be too low to
expand to the number of T cells needed to eradicate the
growing tumor. Thus, the failure of the immune system to
reject tumors could be in part the result of the expansion
of the tumor cell population outpacing that of the specific
T cells. Finally, the stroma of established tumors consists of
nonmalignant, nonantigenic host cells that may prevent
immune destruction (8).
Numerous studies have shown that preventive vaccina-
tions or vaccinations early after tumor cell inoculation can
be effective in inducing rejection of inoculated tumor cells.
However, therapeutic vaccinations at later stages of tumor
growth usually fail (for review see reference 9). While late
vaccination of a tumor-bearing host can induce specific im-
mune responses against antigens expressed by the tumor
and can even lead to rejection of a second fresh tumor cell
challenge, the original tumor is usually not rejected. This
phenomenon is often referred to as concomitant immunity
and is taken as evidence that the established tumor is some-
how protected from immune attack. In at least some tumor
models nonimmunological mechanisms, like the secretion
of the plasminogen fragment angiostatin that results from
the growth of the primary tumor, may cause resistance of
the tumor-bearing host to a second tumor challenge (10,
11). However, other experiments clearly show that anti-
gen-specific immunity can exist in mice carrying long-term
tumors. A striking example of this is the observation that
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tumor-bearing mice can reject allogeneic skin grafts, but
fail to reject the established tumor that expresses the same
alloantigen (12).
Though specific evidence is lacking, it is possible that the
set of self-peptides presented on allogeneic MHC class I
molecules may be different on normal and malignant cells;
therefore, the ability of the tumor-bearing host to reject
normal tissue may result from different T cell clonotypes
responding to the normal allograft. To bypass this possibil-
ity, we used 2C TCR transgenic mice in which all the
CD8
 
1
 
 T cells carry the same TCR specific for an alloanti-
gen expressed by the tumor (13). The 2C TCR recognizes
several closely related natural peptides, all of which are de-
rived from the murine enzyme 
 
a
 
-ketoglutarate dehydroge-
nase (
 
a
 
-KGDH)
 
1
 
, presented by the MHC class I molecule
L
 
d
 
 (14, 15). As a housekeeping protein, 
 
a
 
-KGDH is ex-
pressed by normal and malignant tissues. The use of this
defined transgenic mouse model offers several advantages.
(
 
a
 
) The supply of tumor-specific CD8
 
1
 
 T cells in the trans-
genic mice should be virtually unlimited; thus, we can test
the hypothesis that antigenic cancers grow due to insuffi-
cient numbers of tumor-specific precursor T cells. (
 
b
 
) As far
as we know, the transgenic CD8
 
1
 
 T cells recognize the
same epitopes present on both L
 
d
 
-positive tumors as well as
L
 
d
 
-positive normal tissues; thus, a comparison of the im-
mune responses against malignant and normal tissue should
be possible. In this study, we show that hosts with well-
established tumor burdens showed no evidence of T cell
exhaustion, peripheral anergy, or generalized immune sup-
pression. However, expression of a strong nonself-antigen
on tumors was not sufficient to cause rejection of estab-
lished tumors. Rejection of a tumor cell challenge was ob-
served only after powerful preimmunization of the mice. In
addition, expression of costimulatory molecules by the tu-
mor cells was needed for rejection in 100% of the mice.
 
Materials and Methods
 
Mice and Tumor Lines.
 
Female C3H/HeN (MTV
 
2
 
), BALB/c,
DBA/2, C57BL/6, and athymic nude mice, 4–6 wk old, were
purchased from the National Cancer Institute, Frederick Cancer
Research Facility, (Frederick, MD). The 2C TCR transgenic
mouse strain (13), bearing a TCR recognizing the MHC class I
molecule H-2L
 
d
 
 in association with a set of closely related pep-
tides, was provided by Dr. D. Loh (Washington University, St.
Louis, MO), and was bred and maintained in a specific pathogen-
free barrier facility at the University of Chicago. After back-cross-
ing the 2C TCR transgenic mouse strain to the C57BL/6 strain
for 
 
.
 
10 generations, the mice were crossbred with C3H mice
and the C3H 
 
3
 
 2C TCR F1 mice were used for all experiments.
Expression of the transgenic TCR on CD8
 
1
 
 T cells was deter-
mined by flow cytometry analyses using the clonotype-specific
mAb 1B2 (16). The AG104A fibrosarcoma grew out spontane-
ously in an aging C3H mouse (2 yr and 1 mo old) and was
adapted to culture as described (17). The B7
 
1
 
CD48
 
1
 
AG104A
transfectant of AG104A cells (renamed here AG104ABC) has been
described previously (18). The tumor cell lines were tested regu-
larly for mycoplasma contamination by staining with HOECHST
33258 and examination by immunofluorescence.
 
Transfection of Murine H-2L
 
d
 
.
 
AG104A cells were transfected
by N,N-bis[2-hydroxyethyl]-2-aminoethansulfonic acid (BES) pre-
cipitation with the vector LK444 containing the entire open
reading frame of murine H-2L
 
d
 
 (19), provided by Dr. A. Sant
(University of Chicago), and the transfectants were selected in
DMEM containing 10% FCS (CDMEM) and 500 
 
m
 
g/ml G418.
AG104ABC cells were transfected by electroporation with the same
vector and the pUHD10-3-puro vector containing a puromycin
resistance gene, provided by Dr. D. Mumberg (University of
Chicago), and were selected in DMEM containing 10% FCS and
8.5 
 
m
 
g/ml puromycin. Individual resistant clones were obtained
by limiting dilution cloning and analyzed for L
 
d
 
 expression by
FACS
 
Ò
 
 analysis.
 
Tumor Growth In Vivo and Readaptation to Culture.
 
Tumor cells
were  injected subcutaneously into the flanks of the mice. We in-
jected 5 
 
3
 
 10
 
5
 
 untransfected AG104A wild-type tumor cells
(AG104A–wt) and 2.5 
 
3
 
 10
 
6
 
 transfected AG104A–L
 
d
 
, AG104ABC,
and AG104ABC–L
 
d
 
 tumor cells because these doses yielded tu-
mors with similar rates of growth. Tumor growth was measured
every 3 to 4 d with a caliper. Size in cubic centimeters was calcu-
lated by the formula V 
 
5
 
 
 
p
 
abc
 
/6, where 
 
a
 
, 
 
b
 
, and 
 
c
 
 are three or-
thogonal diameters. At the end of the experiment, animals were
killed and tumor tissue from two or three different locations of
the tumor was reisolated. Tumor fragments were incubated in
CDMEM containing 10% FCS, gentamycin, and penicillin/strepto-
mycin for a few days before analysis.
 
Full-Thickness Skin Grafting.
 
Donor skin was obtained from
the ventral surface of the donor mice (BALB/c or DBA/2) and
applied to the dorsal thoracic wall according to an adaption of the
method of Billingham and Medawar (20). Bandages were re-
moved on day 8 and grafts were monitored daily until rejection
(defined as loss of at least 80% of grafted tissue) or the end point
of the experiment.
 
Immunization Studies.
 
Mice, in groups of six, were injected
intraperitoneally with 5 
 
3
 
 10
 
6
 
 and subcutaneously with 5 
 
3
 
 10
 
6
 
g
 
-irradiated (10,000 rads) AG104A–L
 
d
 
 or AG104ABC–L
 
d
 
 tumor
cells. After 14 d, they were challenged subcutaneously, in groups
of three, with either AG104A–L
 
d
 
 or AG104ABC–L
 
d
 
 cells and tu-
mor growth was measured as described above. As indicated in the
text, L
 
d
 
-negative AG104A–wt tumor cells or AG104ABC tumor
cells were injected on the opposite flank as a specificity control.
 
Generation of Cytolytic L
 
d
 
-specific CTL and an L
 
d
 
-specific T Cell
Clone.
 
Splenocytes were harvested from 2C TCR transgenic
mice and washed once in CDMEM containing 10% FCS. Eryth-
rocytes were removed by centrifugation over Ficoll–Hypaque.
The remaining cells were washed twice and resuspended in
CDMEM.  Cells were then distributed into round-bottomed, 96-
well plates at 0.5 cells/well to be stimulated with mitomycin
C–treated (100 
 
m
 
g/ml for 90 min) P815 mastocytoma cells ex-
pressing murine CD80 (mB7-1; provided by Dr. L. Lanier,
DNAX Research Institute, Palo Alto, CA) in the presence of 20
U/ml recombinant human IL-2 (rhIL-2; Cetus Corporation,
Emeryville, CA) and 10 ng/ml recombinant murine IL-4 (rmIL-4;
Immunex Corporation, Seattle, WA). After 7 d in culture, wells
containing growing T cells were harvested and washed twice in
CDMEM. The T cell clone 900-2 was selected from among these
positive clones and was restimulated in 24-well tissue culture
 
1
 
Abbreviations used in this paper:
 
 
 
a
 
-KGDH, 
 
a
 
-ketoglutarate dehydrogenase;
BES, N,N-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid; CDMEM,
DMEM containing 10% FCS; CTL, cytolytic T lymphocyte(s); MLTC,
mixed lymphocyte–tumor cell culture; rhIL-2, recombinant human IL-2;
rmIL-2, recombinant murine IL-2. 
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plates (Linbro Corporation, ICN Biomedicals, Inc., Aurora, OH)
with 3 
 
3
 
 10
 
5
 
 P815–B7-1 cells/well in the presence of 20 U/ml
rhIL-2. After 3 wk of passage on P815–B7-1 cells, the clone was
restimulated for weekly passage with irradiated (2,000 rads)
DBA/2J splenocytes in 24-well plates (6 
 
3
 
 10
 
6
 
 splenocytes/well,
1 
 
3 
 
10
 
5
 
 T cells/well, 20 U/ml rhIL-2). To compare the cytolytic
activity of T cells from naive and tumor-bearing mice, spleen
cells were incubated with mitomycin C–treated tumor cells in a
mixed lymphocyte–tumor cell culture (MLTC) as previously de-
scribed (17). Cytotoxicity of T cell clones or MLTC effector cells
was determined in a 4.5-h 
 
51
 
Cr release assay at different E/T ra-
tios as described (21). The percentage-specific lysis was calculated
by the formula: percent lysis 
 
5
 
 ([experimental release 
 
2
 
 sponta-
neous release] / [maximum release 
 
2
 
 spontaneous release]) 
 
3
 
100. Spontaneous release was 
 
<
 
15% of maximum. Maximum re-
lease was determined by detergent lysis of targets.
 
Antibodies, Immunostaining, and Flow Cytometry Analyses.
 
Puri-
fied and FITC- or PE-conjugated mAbs to B7-1 (CD80), CD48,
CD8a, and CD4 were purchased from PharMingen Corporation
(San Diego, CA). The mAbs 30-5-7S (anti-H-2L
 
d
 
; reference 22)
and 237 (anti-AG104A; reference 17) were generated as culture
supernatant of the respective hybridomas. The purified mAb 1B2
(anti-2C TCR; reference 16) was a gift of T. Walunas (Univer-
sity of Chicago). Mice were depleted of CD8
 
1
 
 or CD4
 
1
 
 cells by
intraperitoneal injection of 0.2 ml of ascites fluid from nude mice
bearing the rat anti–mouse Lyt-2 hybridoma YTS169.4.2 (anti-
CD8; reference 23) or rat anti–mouse L3T4 hybridoma GK1.5
(anti-CD4; reference 24), respectively. The mice received pro-
phylactic antibiotic in the drinking water (sulfamethoxazole/tri-
methoprin pediatric suspension at 5 ml per 200 ml of water;
Geneva Pharmaceuticals, Broomfield, CO). To measure the lym-
phocyte depletion, peripheral blood from the orbital plexus or
splenic cell suspensions were treated with Tris ammonium chlo-
ride (0.83%) to eliminate erythrocytes and then stained for FACS
 
Ò
 
analysis. Greater than 99% depletion of the specific subset was ob-
served. For immunofluorescence staining, single cell suspensions
of tumor cells, peripheral blood, or spleen were incubated on ice
for 30 min with the indicated reagents in FACS
 
Ò
 
 buffer (PBS 
 
1
 
0.2% BSA 
 
1
 
 0.02% NaN
 
3
 
). After washing three times with FACS
 
Ò
 
buffer, cells were either immediately analyzed or, if unconjugated
antibodies were used for the primary staining, incubated with
FITC-conjugated goat anti–mouse IgG (American Qualex, San
Clemente, CA) or PE-coupled streptavidin (Calbiochem–Nova-
biochem Corporation, La Jolla, CA) at 4
 
8
 
C for 20 min. Follow-
ing three washes with FACS
 
Ò
 
 buffer 10,000 to 25,000 cells were
analyzed on a FACScan
 
Ò
 
 (Becton Dickinson) using LYSIS II soft-
ware.
 
Preparation of Total RNA and cDNA.
 
Total RNA from 5 
 
3
 
10
 
6
 
 cells grown in culture or 30 mg tumor tissue was isolated us-
ing the RNeasy Kit (Qiagen, Hilden, Germany) as prescribed by
the manufacturer. For cDNA synthesis, 4 
 
m
 
g of total RNA were
reverse transcribed in the presence of 1.25 
 
m
 
g oligo(dt)
 
15
 
 primer
(Boehringer Mannheim, Indianapolis, IN) and 300 U M-MLV
reverse transcriptase (GIBCO BRL, Gaithersburg, MD) in a total
volume of 40 
 
m
 
l. No reverse transcriptase was added to the con-
trol samples. Reactions were incubated at 37
 
8
 
C for 60 min and
then heat-inactivated at 95
 
8
 
C for 15 min.
 
PCR Amplification.
 
PCR reactions were performed in a total
volume of 50 
 
m
 
l containing 200 mM dNTPs (Boehringer Mann-
heim), 50 pM oligonucleotide primers, and 0.25 
 
m
 
l Taq poly-
merase (Promega, Madison, WI; 5U/ml). PCR reactions were
subjected to 1-min denaturation at 94
 
8
 
C, 1-min annealing at
60
 
8
 
C, and 1.5-min extension at 72
 
8C. The number of cycles was
determined individually for each primer pair. Primers: b-actin:
forward, 59-GGATGACGATATCGCTGCGCTG-39, reverse,
59-GTACTTCAGGGTCAGGATACCTC-39, Fas ligand: for-
ward, 59-CACTCAAGGTCCATCCCTCTG-39, reverse, 59-TAG-
CTGACCTGTTGGACCTTGC-39.
Results
AG104A Tumor Cells Transfected to Express Ld Grow Pro-
gressively in Anti-Ld TCR Transgenic Mice as Antigen-positive
Tumors. We have shown previously that PRO4L fibro-
sarcoma cells transfected to express certain alloantigens can
grow progressively in immunocompetent mice, while nor-
mal skin transplants expressing the same alloantigens are re-
jected (12, 25). To determine whether this characteristic is
shared by other tumor cell lines, we transfected a poorly
immunogenic C3H fibrosarcoma that arose spontaneously
in an aging mouse with the MHC class I alloantigen Ld.
The transfected AG104A tumor cells (AG104A–Ld) ex-
pressed Ld at a level z40-fold above background as mea-
sured by flow cytometry (Fig. 1 A). Nevertheless all of the
Figure 1. Homogenous ex-
pression of the Ld molecule on
the transfected tumor cells and of
the anti-Ld TCR 2C on the
transgenic CD81 T cells. (A) Sta-
ble transfection of AG104A tu-
mor cells with an Ld cDNA ex-
pression vector resulted in Ld
expression 40-fold above back-
ground as shown by FACSÒ anal-
ysis. Shaded curve, anti-Ld stain-
ing; unshaded curve, staining with
goat anti–mouse FITC secondary
antibody alone. (B) Two-color
staining of peripheral blood cells
from the C3H 3 2C transgenic
mice with biotinylated anti-CD8a,
and 1B2–FITC (anti–2C) mAbs
showed  that all CD81 T cells ex-
press the 2C TCR.232 Growth of Antigenic Tumors without T Cell Exhaustion or Systemic Anergy
C3H 3 C57BL/6 F1 mice developed progressively grow-
ing lethal, antigen-positive tumors when injected subcuta-
neously with AG104A–Ld tumor cells. (Fig. 2 A). The tu-
mor also grew progressively in C3H/HeN mice (data not
shown). We reasoned that the precursor frequency of Ld-
specific T cells in these mice may be too low to match the
rapid growth of the Ld-expressing tumor cells. Therefore,
AG104A–Ld tumor cells were injected into C3H 3 2C
anti-Ld TCR transgenic mice (13) in which all CD81 T cells
express the TCR 2C (see Fig. 1 B) that recognizes the Ld
antigen in association with a set of closely related natural
self-peptides (14, 15). Surprisingly, all of the transgenic
mice developed lethal AG104A–Ld tumors despite the pre-
dominance of the anti-Ld T cells. In addition, the rate of
tumor growth in transgenic mice was unaffected by the
presence of the anti-Ld T cells because similar rates of
growth were also observed in nontransgenic mice (Fig. 2 A)
and nude mice (Fig. 2 B). Reisolation of the AG104A–Ld
tumors showed that the expression of the Ld antigen was
retained in vivo in the nontransgenic (Fig. 2 C) as well as in
the transgenic mice (Fig. 2 D).
Because it has been described that antigen-specific T cells
can undergo apoptotic death due to Fas ligand expression
on the target tumor cells (2–4), we analysed in vitro and in
vivo grown AG104A–Ld cells for the expression of Fas
ligand by PCR analysis. Neither AG104A–Ld cells grown
in culture nor AG104A–Ld cells reisolated from a tumor
grown in vivo expressed Fas ligand (Fig. 3). Activated T cells,
which expressed Fas ligand, were used as positive control
and analysis of Fas ligand expression in the absence of re-
verse transcriptase showed that this signal was not due to
genomic DNA contamination.
Ld-positive Normal Skin Is Rejected by CD81 Lymphocytes
in the Anti-Ld TCR Transgenic Mice. Allogeneic full-thickness
skingrafts are rejected by normal, immunocompetent mice
about 12–13 d after transplantation even when grafts are
antigenically disparate from the recipient in only one MHC
locus (12). Table 1 shows that the anti-Ld TCR transgenic
mice could reject Ld-positive full-thickness skin allografts as
effectively as nontransgenic littermates. Furthermore, treat-
ment of the mice with anti-CD8 antibody, but not anti-
CD4 antibody, prevented this rejection. Flow cytometric
analysis of the lymphocytes from the antibody-treated mice
revealed specific and complete elimination of the T cell
subsets (data not shown). These results showed that the
CD81 T cell compartment of the transgenic mice is neces-
sary for skin graft rejection and does not require CD41 T
cells.
Figure 2. AG104A–Ld tumor cells grow progressively and retain Ld ex-
pression in normal C3H 3 C57BL/6 mice and anti-Ld TCR transgenic
mice. AG104A–Ld cells were injected subcutaneously into the flanks of
four normal C3H 3 C57BL/6 mice and five anti-Ld C3H 3 2C TCR
transgenic mice (A) or two nude mice and three anti-Ld C3H 3 2C
TCR transgenic mice (B). Tumors grew out in all types of mice. Bars in-
dicate the SEM. FACSÒ analysis of AG104A–Ld tumor cells reisolated at
day 27 from a nontransgenic mouse (C) or at day 33 from a TCR trans-
genic mouse (D) showed that antigen expression was retained in the
course of tumor growth. Shaded curve, anti-Ld staining; unshaded curve,
staining with goat anti–mouse FITC secondary antibody alone.
Figure 3. AG104A–Ld tumor cells do not express Fas ligand. Total
RNA was isolated from AG104A–Ld tumor cells grown in culture or as
tumors in vivo, P815 tumor cells, and spleen cells. Total RNA from the
T cell clone pGL10 (37), activated for 7 d on syngeneic feeder cells in the
presence of 0.2 mg/ml chicken ovalbumin and 12 IU/ml rhuIL-2, was
provided by Dr. U. Korthäuer (University of Chicago). Expression of Fas
ligand and b-actin was analyzed by RT-PCR. To test for genomic DNA
contamination, RT-PCR was also performed without the addition of re-
verse transcriptase for the cDNA synthesis (no RT).233 Wick et al.
AG104A–Ld Tumor Cells Are Sensitive In Vitro to Preacti-
vated CD81 Cytolytic T Cells. Because the anti-Ld TCR
transgenic mice failed to reject Ld-positive tumor cells, but
rejected Ld-positive skin grafts, we determined whether the
tumor cells could be lysed in vitro by Ld-specific T cells ex-
pressing the 2C clonotype. Fig. 4 shows that the Ld-trans-
fected AG104A tumor cells were lysed specifically in a 4.5-h
51Cr release assay by the anti-Ld CD81 cytolytic T cell clone
900-2 derived from the transgenic mice. This result showed
that the failure of the AG104A–Ld tumor cells to be re-
jected by the C3H 3 2C mice was not because the tumor
cells were resistant to lysis by the transgenic T cells.
Failure of the Anti-Ld TCR Transgenic Mice to Reject Ld-pos-
itive Tumor Cells Is Not Due to Clonal Exhaustion or Systemic
Anergy. Whereas AG104A–Ld tumor cells can be lysed by
preactivated cytolytic T cells in vitro, the activation of the
anti-Ld T cells by the tumor in vivo may be inefficient.
Rejection of full-thickness skin grafts is a powerful immu-
nization procedure, probably owing to the abundance of
dendritic cells (Langerhans cells) in the skin. Therefore, to
determine whether activation of the T cells by skin graft
rejection would also lead to rejection of the tumor, we in-
oculated TCR transgenic mice with Ld-positive tumor cells
at the same time that we transplanted Ld-positive skin onto
these mice. Mice rejected the skin grafts at day 13 after
transplantation; however, there was no effect on the growth
of the Ld-positive tumors that were already well established
at this time (Fig. 5, A and C). The outgrowth of the Ld-posi-
tive tumors was not due to antigen loss, because FACSÒ
analysis of the tumors reisolated at day 24 showed no loss
or decrease in Ld expression (Fig. 5, B and D).
The tumors described in the previous experiment were
still in earlier stages of growth (day 13) at the time the skin
graft was rejected by the mice. Therefore, it could be ar-
gued that at that early time sufficient T cells were still avail-
able to reject the skin graft, whereas at later stages the
CD81 L d-specific T cells were functionally or physically
exhausted from the tumor-bearing host. Thus, we placed
full-thickness BALB/c skin grafts on five anti-Ld TCR
transgenic mice bearing AG104A–Ld tumors for 2, 3, or
4 wk. We found that even these late tumor-bearing mice
Table 1. Anti-Ld TCR Transgenic Mice Reject Ld-positive Full-Thickness Skin Allografts as Effectively as Nontransgenic Littermates
Recipient Strain of origin
of Ld-positive
full-thickness skin Take of graft Survival of graft Strain Antibody treatment
d 6 SD*
C3H 3 2C (TCR transgenic) None BALB/c 0/34 13 6 1
None DBA/2 0/12 13 6 1
Anti-CD4 BALB/c 0/2 13 6 1
Anti-CD8 BALB/c 3/3 .24
C3H 3 C57BL/6 (nontransgenic) None BALB/c 0/2 12
None DBA/2 0/4 12 6 1
BALB/c None BALB/c 8/8 .24
DBA/2 None DBA/2 3/3 .24
*Day of rejection as mean 6 standard deviation.
Figure 4. An anti-Ld–specific CD81 T cell clone from TCR transgenic
mice has cytolytic activity against AG104A–Ld and AG104ABC–Ld tu-
mor cells in vitro. The CD81 T cell clone 900-2 derived from the 2C
TCR transgenic mice specifically recognizes and lyses AG104A–Ld and
AG104ABC–Ld tumor cells, but not AG104A–wt tumor cells in a 4.5-h
51Cr release assay in vitro.234 Growth of Antigenic Tumors without T Cell Exhaustion or Systemic Anergy
completely rejected the skin grafts, although with a 2–3 d
delay when compared with nontumor-bearing mice (data
not shown). This result indicates that even at a late stage of
tumor growth, the relevant T cells were still present to re-
ject the skin graft. However, there was no detectable effect
of the graft rejection on the growth of the Ld-positive tu-
mor (data not shown).
Expression of Costimulatory Molecules by the Ld-positive Tumor
Cells Leads to Slower Tumor Growth in Anti-Ld TCR Trans-
genic Mice. The above experiments showed that mice
bearing early or late Ld-positive tumors can show specific
immunity against Ld-positive skin tissue without detectable
effects on tumor growth. Because skin tissue differs from
tumor tissue in that it contains a high number of potent an-
tigen-presenting cells (Langerhans cells) that express co-
stimulatory molecules, we determined whether expression
of costimulatory molecules by the growing tumor would
suffice to activate the CD81 T cells and result in tumor re-
jection. We introduced an Ld expression vector into
AG104A cells already transfected to express B7-1 and CD48
(18; renamed AG104ABC cells). The expression level of Ld,
B7-1 and CD48 in these triple transfectants (AG104ABC–Ld),
also shown in Fig. 6 A, is 15-fold, 200-fold, and 11-fold
above background, respectively. AG104ABC–Ld cells were
sensitive to lysis in vitro by the anti-Ld CD81 T cell clone
900-2 in a 4.5-h 51Cr release assay (see Fig. 4). However,
10 of the 11 anti-Ld transgenic mice failed to reject the
challenge of AG104ABC-Ld tumor cells (tumor incidence
91%; Table 2). In nine of the mice, the outgrowth of
AG104ABC–Ld was significantly slower as compared with
tumor cells expressing only the Ld antigen, but no costimu-
latory molecules (Fig. 6 B). Nevertheless, the AG104ABC–Ld
tumors grew out to kill the animals. An additional mouse
showed a persistent nongrowing 1-mm3 firm nodule that
contained AG104ABC–Ld tumor cells upon reisolation and
FACSÒ staining with AG104A-specific and Ld-specific
mAbs. Only one mouse rejected the tumor cell challenge
completely. The untransfected tumor cells or those ex-
pressing only Ld or B7 and CD48 grew progressively in all
of the mice (Table 2).
Only Ld-positive Tumor Cells that Provide Costimulation Are
Rejected after Preimmunization. To test whether CD81 T
cells from anti-Ld TCR transgenic mice may be more ef-
fective in rejecting the Ld-positive tumor cells after pre-
immunization, the anti-Ld TCR transgenic C3H 3 2C
mice were immunized either with Ld-positive (BALB/c)
full-thickness skin grafts or with lethally irradiated AG104A
tumor cells expressing either Ld alone or in combination
with B7-1 and CD48. Immunization with the transfected
tumor cells caused only minimal reduction in the rate of
growth of a subsequent challenge with AG104ABC–Ld or
AG104A–Ld tumor cells (Table 2); each of the four groups
showed progressive tumor growth in all mice. By contrast,
immunization with the Ld-positive skin caused full protec-
tion against a subsequent challenge with AG104ABC–Ld
tumor cells (Fig. 7 A), but only a partial protection against
Figure 5. Anti-Ld TCR transgenic mice reject Ld-positive skin, but do
not reject a simultaneous challenge with Ld-expressing tumor cells. Two
TCR transgenic mice were transplanted with full-thickness Ld-positive
skin from a BALB/c mouse and concurrently received subcutaneous in-
jections of AG104A–wt cells and AG104A–Ld cells on opposite flanks.
Whereas both mice rejected the skin graft at day 13 after transplantation
(see Table 1), both wt and Ld-expressing tumors grew progressively (A
and C). Bars indicate the SEM. The outgrowth of AG104A–Ld was not
due to antigen loss, because tumor cells reisolated on day 24 still stained
positive for Ld in a FACSÒ analysis (B and D). Shaded curve, anti-Ld stain-
ing, unshaded curve, staining with goat anti–mouse FITC secondary anti-
body alone.
Figure 6. Expression of the costimulatory molecules B7-1 and CD48
by the Ld-positive AG104A tumor cells leads to slower tumor outgrowth
in naive TCR transgenic mice. AG104A cells expressing the costimula-
tory molecules B7-1 and CD48 (18) were transfected with an Ld cDNA
expression vector. The expression level of Ld, B7-1, and CD48 in these
triple transfected cells, named AG104ABC–Ld, is shown in A. To deter-
mine the effect of expression of B7-1 and CD48 on tumor cell outgrowth
(B), naive TCR transgenic mice were injected with either AG104A–Ld
cells (3 mice) or AG104ABC–Ld cells (11 mice). AG104ABC–Ld tumor
cells grew slower than AG104A–Ld tumor cells. Bars indicate the SEM.235 Wick et al.
AG104A–Ld tumor cells (Table 2). Protective immuniza-
tion by Ld-positive skin grafts was antigen specific, because
there was no protection against Ld-negative AG104A tu-
mor cells whether or not transfected with B7-1 and CD48
(Fig. 7 A; Table 2). The rejection of the tumor challenge
was dependent upon CD81 T cells, because the tumor cells
grew progressively in two mice treated with anti-CD8 an-
tibody, while the rejection of the tumor cells was unaf-
fected in the two mice treated with anti-CD4 antibody
(Fig. 7, B and C). Furthermore, the mice that had rejected
the AG104ABC–Ld tumor cells after immunization with
the Ld-positive skin grafts mounted stronger Ld-specific re-
sponses in vitro (Fig. 7 D) than naive mice (Fig. 7 E) or
mice that only rejected Ld-positive skin (data not shown).
Discussion
Our initial experiments in this study showed that normal
C3H or C3H 3 C57BL/6 F1 mice were able to reject skin
grafts expressing the MHC class I alloantigen Ld, but failed
to reject Ld-transfected tumor cells. We reasoned that an al-
ternate set of predominant self-peptides may be presented
in the context of this MHC class I molecule in normal and
malignant tissue. Therefore, the two types of transplants
may affect various Ld-specific T cell clonotypes differently.
Furthermore, it is possible that the precursor frequency of
Ld-specific T cells in these mice may simply not be suffi-
cient to prevent the tumor cells from growing. Therefore,
we examined how mice transgenic for the anti-Ld TCR
2C (13) would respond to skin grafts and tumor cell chal-
lenges expressing the Ld antigen. The 2C TCR is expressed
on all CD81 T cells of these mice (13) and specifically rec-
ognizes Ld in combination with a closely related set of pep-
tides derived from the ubiquitously expressed housekeeping
enzyme  a-KGDH (14, 15). Surprisingly, we found that
TCR transgenic mice rejected Ld-positive full-thickness skin
grafts, but at the same time failed to reject Ld-positive tu-
mor cells. Even transgenic mice bearing an Ld-expressing
Table 2. Incidence (%) of AG104A Tumors in Anti-Ld TCR Transgenic Mice
Treatment of TCR 
transgenic mice
Tumor incidence (%) in mice challenged with
AG104A–wt and AG104A–Ld* or AG104ABC and AG104ABC–Ld‡
None 13/13 (100) 13/13 (100) 11/11 (100) 10/11 (91)
Preimmunization
with irradiated
AG104A–Ld cells§ 3/3 (100) 3/3 (100) 3/3 (100) 3/3 (100)
Preimmunization
with irradiated
AG104ABC–Ld cells§ 3/3 (100) 3/3 (100) 3/3 (100) 3/3 (100)
Preimmunization
by rejection of Ld-positive skini 15/15 (100) 8/18 (44) 6/6 (100) 0/6 (0)
*Mice were challenged with AG104A–wt cells and AG104A–Ld cells on opposite flanks.
‡Mice were challenged with AG104ABC cells and AG104ABC–Ld cells on opposite flanks.
§Irradiation with 10,000 rads was required to prevent outgrowth of the tumor cell inoculum used for vaccination in the TCR transgenic mice.
iMice were challenged with tumor cells 3–5 d after rejection of Ld-positive skin (see Table 1).
Figure 7. Antigen-positive tumor cells providing costimulation are ef-
fectively rejected after preimmunization of TCR transgenic mice with
antigen-positive skin. Six TCR transgenic mice were challenged subcuta-
neously with AG104ABC–Ld tumor cells and AG104ABC tumor cells on
opposite flanks 3–5 d after rejection of a full-thickness BALB/c skin graft.
All six mice rejected the AG104ABC–Ld tumor cells, but not the simulta-
neous AG104ABC tumor cell challenge, showing that the protective ef-
fect of Ld-positive skin was antigen specific (A). Four mice, each of which
rejected the skin graft, were treated with anti-CD8 antibody (B) or anti-
CD4 antibody (C) 3 d before challenge with AG104ABC–Ld tumor cells.
The tumors grew in the anti-CD8–treated mice, but not in the anti-
CD4–treated mice, showing that tumor rejection is mediated by CD81
T cells. Spleen cells from the six mice that rejected the AG104ABC–Ld
tumor cells (D) and six naive TCR transgenic mice (E) were stimulated in
vitro with AG104A–Ld tumor cells in a MLTC. Specific cytolytic T cells
were detected only in the culture from mice that had rejected the
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tumor for two to four weeks were still able to reject Ld-
positive skin without any detectable effect on the further
outgrowth of the tumor. Thus, antigenic cancer cells can
still grow progressively when all of the CD81 T cells in the
host are specific for an antigen on the tumor. Only after
prior activation of the CD81 T cells by the rejection of an-
tigen-positive skin could about half of the transgenic mice
eliminate a subsequent antigen-positive tumor cell chal-
lenge.
One reason for the failure to reject antigen-positive tu-
mor cells could be that the Ld-specific CD81 T cells in the
TCR transgenic mice were not fully functional or were
lacking sufficient help for activation due to a reduced num-
ber of CD41 T cells in these mice (26). However, the
rejection of Ld-positive skin shows that the transgenic mice
were able to mount an Ld-specific immune response as well
as nontransgenic mice. Using subset specific antibodies, we
showed that the Ld-specific CD81 T cells were necessary
for the rejection of the skin and that CD41 T cells were not
required for this effect. In addition, rejection of AG104ABC–Ld
by preimmunized mice also did not require CD41 T cells,
indicating that CD41 T cell help is not required for CD81
T cell activation in this model. An alternative explanation
could be that the tumor cells express insufficient numbers
of the relevant peptide–MHC complexes on the cell sur-
face to trigger lysis by the transgenic T cells. It has been re-
ported that different closely related peptides derived from
the a-KGDH enzyme can be presented on Ld and are rec-
ognized by the 2C TCR with different affinities (14, 15,
27). We do not know whether the tumor cells produce all
of these peptides. In addition, the abundance of these pep-
tides in different tissues varies profoundly (28). However,
the Ld-transfected AG104A tumor cells represented sensi-
tive targets in vitro for an Ld-specific CD81 cytolytic T cell
clone derived from the transgenic mice, indicating that
there is sufficient quantity of the Ld–peptide complexes on
the AG104A–Ld tumor cells to promote lysis in vitro. Also,
AG104A–Ld cells appeared to remain sensitive to lysis in
vivo, because intravenous injection of those tumor cells
along with the in vitro–activated transgenic CTL clone sig-
nificantly reduced the number of lung metastases (data not
shown). Finally, the tumor cells that grew out were not se-
lected for antigen loss, because analysis of cells reisolated
from AG104A–Ld tumors showed that progressively grow-
ing tumor cells still expressed Ld.
An adverse local environment generated by tumor cells
could account for the escape from immune destruction. In
some tumor models, the established tumor graft inhibits the
outgrowth of the other grafts by preventing vascularization
(10, 11). However, in our model the antigenic skin grafts
were fully vascularized and healed-in before being rejected;
thus, vascular establishment per se did not allow the anti-
genic skin to avoid immune destruction in the tumor-bear-
ing host. Another effective way for antigenic tumors to es-
cape immunological rejection is the expression of Fas ligand,
which induces apoptosis of the tumor-infiltrating lympho-
cytes by the engagement of Fas on the T cells (2–4). Such a
mechanism may ultimately lead to the exhaustion of the
antigen-specific T cells in hosts with large tumor burdens,
comparable to the T cell exhaustion observed as a result of
persistent viral infections (29, 30). Furthermore, systemic
T cell signaling defects have been described, particularly in
late tumor-bearing hosts (31–33). However, we showed
that AG104A–Ld tumor cells do not express Fas ligand in
vitro or in vivo. Also, systemic defects in T cell signaling
per se most likely do not account for the failure of tumor
rejection, because mice had 13-d-old established tumors when
they rejected the skin grafts and even late tumor-bearing
hosts (.5 wk) with large tumors could still reject skin grafts
with a 2–3-d delay when compared with control mice.
These data also indicated that there was no general exhaus-
tion of the antigen-specific T cells by the growing tumor.
In addition to the interaction between the MHC class
I–peptide complex and the respective TCR, costimulatory
signals are necessary for efficient activation of CD81 T
cells. Absence of costimulatory molecules on tumor cells
can result in an unresponsive state or apoptotic cell death of
specifically reactive T cells (for an overview see references
1, 34). Consistent with this concept, tumor cells transfected
to express costimulatory molecules can induce more effec-
tive immunity than untransfected tumor cells (18, 35, 36).
Therefore, one attractive explanation for the differential re-
sponse of the transgenic mice to the two tissues, i.e., rejec-
tion of the antigen-positive skin and the persistence of
the tumor, could be the differences in local T cell activa-
tion by these two types of tissues. In contrast with the
tumor, skin is rich in potent antigen-presenting dendritic
cells, the Langerhans cells, which express costimulatory mole-
cules as well as the target antigen. However, the lack of co-
stimulation may not be sufficient to explain inefficient tu-
mor rejection, because Ld-positive AG104A tumor cells
expressing the costimulatory molecules B7-1 and CD48
still grow progressively, though at a reduced rate. Only af-
ter preimmunization by rejection of antigen-positive skin,
were AG104ABC–Ld cells completely eliminated. Preim-
munization with Ld-positive skin was much more effective
in inducing an anti-Ld tumor response than preimmuniza-
tion with lethally irradiated AG104A–Ld cells transfected to
express the costimulatory molecules B7-1 and CD48. Pos-
sibly, the large dose of x ray we used may have shortened
the survival of the immunizing cells and lessened the effec-
tiveness of the immunization. However, the amount of ir-
radiation we used was needed to prevent in vitro and in
vivo growth of the tumor cells used for vaccination.
Taken together, our results point out critical problems
for inducing anti-tumor immune responses. Using a TCR
transgenic mouse model we could show that, even in the
absence of systemic anergy or clonal exhaustion, a very
high number of tumor-specific precursor CD81 T cells per
se was not sufficient for tumor rejection in vivo. Tumor
cell challenges were only rejected effectively after prior ac-
tivation of the CD81 T cells by preimmunization and
when the cells used for tumor challenge were manipulated
so that they also expressed costimulatory molecules. Only237 Wick et al.
the most potent immunization, rejection of antigen-posi-
tive full-thickness skin, was successful in inducing immu-
nity that could lead to the rejection of a subsequent antigen-
positive tumor challenge. Although we are not certain why
preimmunization was needed, it may be that these T cells
are activated more effectively and recirculate to enter the
tumor site, and/or are more resistant to an adverse intratu-
mor environment. Immunization started at the time of tu-
mor inoculation or thereafter did not influence the tumor
outgrowth, indicating that the establishment of the solid
tumor prevented therapy. During tumor establishment,
cancer cells become surrounded by nonantigenic stroma (in-
terstitial cells and vessels), which can clearly counteract ef-
fective immunological rejection (8). By contrast, antigenic-
ity of the stroma of normal tissue allografts is a major reason
for effective rejection of such grafts. Therefore, it is possi-
ble that the nonantigenic stroma of cancers may prevent
tumor-specific T cells from being attracted to and penetrat-
ing into the tumor. This is consistent with our finding that
the Ld-positive tumors, once established in the TCR trans-
genic mice, are not infiltrated by T cells (data not shown).
In summary, our results show that even an abundance of
tumor-specific T cells and vigorous active immunization
procedures such as rejection of a full-thickness skin graft are
insufficient to cause rejection of established tumors. Thus, a
critical hurdle for the immunotherapy of cancer may be to
find effective ways to direct tumor-specific T cells into es-
tablished tumors and to activate them at the tumor site.
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